Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 326 matching trials from the live ClinicalTrials.gov search.
Conditions
Type 2 Diabetes
Interventions
CuraLin
Dietary Supplement
Lead sponsor
National University of Natural Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Conditions
Hip Osteoarthritis, Hip Arthropathy
Interventions
Pericapsular Nerve Block, Fascia Iliaca Nerve Block
Drug
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years to 80 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Chronic Heart Failure
Interventions
MTP-101-C encapsulated Microbiota, Vancomycin, Neomycin
Biological · Drug
Lead sponsor
Melana Yuzefpolskaya, MD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Inborn Errors of Bile Acid Synthesis
Interventions
Cholic acid
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Pulmonary Infections, Pseudomonas Aeruginosa in Cystic Fibrosis
Interventions
TBM100
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
20
States / cities
Little Rock, Arkansas • Denver, Colorado • Jacksonville, Florida + 16 more
Conditions
Obesity
Interventions
GF-IGB: Obalon Balloon, Medically Supervised Meal Replacement Program: My New Weigh, Endoscopic sleeve gastroplasty: (ESG)
Device · Dietary Supplement · Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
22 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Endothelial Dysfunction
Interventions
atrasentan
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Depression, Depressive Disorder, Major, Depressive Disorder, Unipolar Depression, Major Depressive Disorder
Interventions
Venlafaxine XR, Aerobic Exercise, Lorazepam
Drug · Other
Lead sponsor
Kirk Erickson, PhD
Other
Eligibility
60 Years to 79 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Neuropsychiatric Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE), Cognitive Impairment
Interventions
Placebo, EG-501
Drug
Lead sponsor
Evergreen Therapeutics, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Cleveland, Ohio • Nashville, Tennessee • Houston, Texas
Conditions
Epilepsy, Epilepsy in Children, Epilepsy; Seizure, Disease, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Epileptic Syndromes
Interventions
XEN496
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
1 Month to 6 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Tacoma, Washington
Conditions
Anterior Cruciate Ligament Reconstruction, Total Hip Arthroplasty (THA), Total Knee Arthroplasty, Hip Arthroscopy
Interventions
Visualization training with neurofeedback, Standard post-surgical rehabilitation therapy
Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Major Depression, Healthy Participants
Interventions
Sham iTBS, TMS, D-cycloserine, Dextromethophan, Placebo
Device · Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Belmont, Massachusetts
Conditions
Candidemia, Candidiasis, Invasive
Interventions
Fosmanogepix, Caspofungin, Fluconazole, Placebo
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 17 more
Conditions
Inflammatory Bowel Diseases, Clostridioides Difficile Infection
Interventions
Xylitol, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Boston, Massachusetts
Recruiting Early Phase 1 Interventional

SGLT2i in Kidney Stones

NCT07055282
Conditions
Kidney Stones
Interventions
Empagliflozin (Jardiance®)
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Advanced Solid Tumors With HER2 Abnormalities, Advanced Solid Tumors With HER3 Abnormalities
Interventions
TAS0728
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Duarte, California • Atlanta, Georgia • New York, New York + 2 more
Conditions
Leukemia, Myelofibrosis, Anemia, Splenomegaly
Interventions
Rigosertib, Questionnaire
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hyperprolactinemia
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Catonsville, Maryland
Conditions
Alcohol Use Disorder
Interventions
Zonisamide, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 70 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Farmington, Connecticut • New Haven, Connecticut • West Haven, Connecticut + 1 more
Conditions
Postoperative Urinary Tract Infection
Interventions
Tamsulosin, Control Group
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
50 Years and older · Male only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Conditions
HIV Infection
Interventions
Polyphenon E, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Houston, Texas
Conditions
Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Ph- Acute Lymphoblastic Leukemia (Ph-ALL), Chronic Myeloid Leukemia Accelerated Phase (CML-AP, Ph+), Chronic Myeloid Leukemia Blast Crisis (CML-BC, Ph+)
Interventions
ETC-1907206, dasatinib
Drug
Lead sponsor
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Government
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
5
States / cities
Atlanta, Georgia • Bethesda, Maryland • New York, New York + 2 more
Completed Phase 2Phase 3 Interventional Results available

A Trial of Levodopa in Angelman Syndrome

NCT01281475
Conditions
Angelman Syndrome
Interventions
Levodopa, Placebo Oral Capsule
Drug
Lead sponsor
Wen-Hann Tan
Other
Eligibility
4 Years to 12 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
7
States / cities
San Diego, California • San Francisco, California • Boston, Massachusetts + 4 more
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Pediatric Concussion Outcomes

NCT04226365
Conditions
Concussion Post Syndrome, Headaches Posttraumatic, Mild Traumatic Brain Injury
Interventions
Nortriptyline, Placebo
Drug
Lead sponsor
Lancaster General Hospital
Other
Eligibility
13 Years to 21 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Lancaster, Pennsylvania